Background
TB kills 1.3 million persons annually, including 275,000 people in India. An estimated 40% of the population in India has LTBI (Latent Tuberculosis Infection), a significant percentage of them being infected with HIV. HIV infection increases the likelihood of LTBI progressing to active TB. Vaccination and immunotherapeutic strategies are alternative approaches that contribute greatly to TB control in HIV+ persons with LTBI.
Methods
Peripheral blood was drawn from, HIV+ and HIV- individuals with and without LTBI. PBMC and CD14+ monocytes were isolated and 2 million cells were cultured with γ irradiated M. tuberculosis H37Rv, CFP-10. Cultures were terminated after 96 hours, and cells were stained for CD4, CD25, FOXP3 and D4GDI. IFN-γ, IL-17, IL-22 were estimated in the supernatants by ELISA. RNA was isolated from CD14 cells and Realtime PCR was performed to quantitate c-maf expression. P<0.05 was considered statistically significant.
Anzeige
Results
In response to M. tuberculosis, FoxP3+ cells expand in HIV+ and healthy LTBI+ donors. In contrast, D4GDI+FoxP3+ cells expand only in healthy LTBI+ individuals. IL-17 and IL-22 are significantly high in HIV-LTBI+ individuals, increased c-maf expression in monocytes was observed in HIV+ LTBI+ individuals
Conclusions
IL-17 and IL-22 can be helpful to control reactivation of tuberculosis in HIV+ individuals.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.